Biogen Inc. BIIB
We take great care to ensure that the data presented and summarized in this overview for BIOGEN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BIIB
View all-
Vanguard Group Inc Valley Forge, PA16.6MShares$3.7 Billion0.07% of portfolio
-
Primecap Management CO Pasadena, CA16.2MShares$3.62 Billion2.65% of portfolio
-
Black Rock Inc. New York, NY14.1MShares$3.16 Billion0.07% of portfolio
-
State Street Corp Boston, MA6.75MShares$1.51 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.17MShares$1.15 Billion0.68% of portfolio
-
Wellington Management Group LLP Boston, MA5.12MShares$1.14 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY4.69MShares$1.05 Billion0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA3.41MShares$761 Million0.07% of portfolio
-
Van Eck Associates Corp1.74MShares$388 Million0.58% of portfolio
-
Morgan Stanley New York, NY1.7MShares$380 Million0.03% of portfolio
Latest Institutional Activity in BIIB
Top Purchases
Top Sells
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BIIB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 21
2024
|
Jesus B Mantas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+15.35%
|
-
|
Jun 21
2024
|
Stephen A Sherwin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+6.26%
|
-
|
Jun 21
2024
|
Monish D Patolawala Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+50.0%
|
-
|
Jun 21
2024
|
Susan Langer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+32.69%
|
-
|
Jun 21
2024
|
Eric K Rowinsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+5.75%
|
-
|
Jun 21
2024
|
Maria C Freire Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+23.16%
|
-
|
Jun 21
2024
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,340
+17.11%
|
-
|
Jun 21
2024
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,785
+6.29%
|
-
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
SELL
Payment of exercise price or tax liability
|
Direct |
276
-29.42%
|
$59,616
$216.13 P/Share
|
May 01
2024
|
Adam Keeney Head of Corporate Development |
BUY
Exercise of conversion of derivative security
|
Direct |
938
+50.0%
|
-
|
Apr 02
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
93
-1.87%
|
$19,809
$213.09 P/Share
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
SELL
Payment of exercise price or tax liability
|
Direct |
117
-1.2%
|
$25,038
$214.83 P/Share
|
Apr 01
2024
|
Nicole Murphy Head of Pharm Ops and Tech |
BUY
Exercise of conversion of derivative security
|
Direct |
240
+2.4%
|
-
|
Feb 22
2024
|
Priya Singhal Head of Development |
SELL
Open market or private sale
|
Direct |
262
-5.09%
|
$57,902
$221.23 P/Share
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,437
-2.32%
|
$533,703
$219.08 P/Share
|
Feb 16
2024
|
Susan H Alexander EVP Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,037
+4.55%
|
-
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
2,264
-7.9%
|
$495,816
$219.08 P/Share
|
Feb 16
2024
|
Ginger Gregory EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
4,704
+13.88%
|
-
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,438
-8.33%
|
$752,922
$219.08 P/Share
|
Feb 16
2024
|
Michael R Mcdonnell EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,720
+13.79%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 11.2K shares |
---|---|
Exercise of conversion of derivative security | 59K shares |
Open market or private purchase | 455 shares |
Payment of exercise price or tax liability | 24.2K shares |
---|---|
Open market or private sale | 2.14K shares |